Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK138D1 in advanced solid tumors
NCT06730386Phase 1Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK138D1 in solid tumor (advanced stage), sponsored by Akeso, Inc. Primary endpoints: Adverse Events and Dose-limiting toxicity. Started Feb 2025; status: recruiting.
02
Drugs
AK138D1
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06730386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730386.